Log in

Liberty Media Formula One Series C (NASDAQ:FWONK) Earns Buy Rating from B. Riley

Last updated on Tuesday, June 30, 2020 | 2020 MarketBeat

Liberty Media Formula One Series C (NASDAQ:FWONK)'s stock had its "buy" rating restated by analysts at B. Riley in a report released on Tuesday, TipRanks reports. They presently have a $39.00 price target on the stock. B. Riley's price objective suggests a potential upside of 26.42% from the company's previous close.

Other equities analysts have also issued reports about the company. Zacks Investment Research upgraded Liberty Media Formula One Series C from a "sell" rating to a "hold" rating in a research note on Monday, June 15th. ValuEngine upgraded Liberty Media Formula One Series C from a "hold" rating to a "buy" rating in a research note on Tuesday, March 10th. Morgan Stanley upped their target price on Liberty Media Formula One Series C from $30.00 to $32.00 and gave the stock an "equal weight" rating in a research note on Friday, May 8th. Finally, Pivotal Research upped their price objective on Liberty Media Formula One Series C from $35.00 to $42.00 and gave the stock a "buy" rating in a report on Tuesday, May 19th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock has an average rating of "Buy" and an average price target of $41.20.

NASDAQ:FWONK opened at $30.85 on Tuesday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.65 and a current ratio of 0.65. Liberty Media Formula One Series C has a 52-week low of $18.31 and a 52-week high of $48.95. The firm has a market cap of $7.15 billion, a price-to-earnings ratio of -14.15 and a beta of 1.30. The business's fifty day moving average is $33.53 and its 200 day moving average is $36.56.

Liberty Media Formula One Series C (NASDAQ:FWONK) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.92) by ($0.56). The company had revenue of $39.00 million for the quarter, compared to the consensus estimate of $25.00 million. Liberty Media Formula One Series C had a negative net margin of 27.88% and a negative return on equity of 2.29%. Equities analysts predict that Liberty Media Formula One Series C will post -1.56 EPS for the current fiscal year.

A number of hedge funds have recently modified their holdings of the stock. First Republic Investment Management Inc. boosted its holdings in Liberty Media Formula One Series C by 3.0% during the 4th quarter. First Republic Investment Management Inc. now owns 7,963 shares of the company's stock valued at $366,000 after acquiring an additional 235 shares during the period. Brinker Capital Inc. raised its position in Liberty Media Formula One Series C by 1.4% during the 4th quarter. Brinker Capital Inc. now owns 17,347 shares of the company's stock valued at $797,000 after purchasing an additional 238 shares during the last quarter. Bank of Montreal Can raised its position in Liberty Media Formula One Series C by 0.7% during the 4th quarter. Bank of Montreal Can now owns 39,281 shares of the company's stock valued at $1,806,000 after purchasing an additional 274 shares during the last quarter. Prudential Financial Inc. raised its position in Liberty Media Formula One Series C by 7.7% during the 4th quarter. Prudential Financial Inc. now owns 5,610 shares of the company's stock valued at $258,000 after purchasing an additional 400 shares during the last quarter. Finally, Signaturefd LLC raised its position in Liberty Media Formula One Series C by 38.3% during the 1st quarter. Signaturefd LLC now owns 1,498 shares of the company's stock valued at $41,000 after purchasing an additional 415 shares during the last quarter. Institutional investors own 82.66% of the company's stock.

About Liberty Media Formula One Series C

Formula One Group operates in the motorsports business. It holds commercial rights for the world championship, a motor race-based competition in which teams compete for the constructors' championship and drivers compete for the drivers' championship. The company is based in Englewood, Colorado.

See Also: Liquidity

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

8 Pharmaceutical Companies Working on a Coronavirus Cure

We are living through interesting times. Not an hour goes by when Americans don’t receive some reminder of the impact the coronavirus has on our lives. The race is on for an effective, FDA-approved treatment for the virus. Despite, vaccines being available for human trial in record time, we are many months away from having a viable vaccine.

However, we may be somewhat closer in finding some antiviral treatments. And if you’ve watched the market closely this week, any news on that front tends to move the market in a positive direction.

That brings up another truth of investing. There are some stocks that thrive from other stocks misery. And that’s why we’ve put together this special report. If you’re an investor who is looking to jump into this bear market, the pharmaceutical sector is a logical choice.

A combination of big-name drug companies as well as smaller startup companies are working around the clock to develop vaccines or treatments that will target the infection caused by the novel coronavirus.

View the "8 Pharmaceutical Companies Working on a Coronavirus Cure".

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.